文献类型：期刊文献

中文题名：副干酪乳酪杆菌LPB27对肠道菌群的潜在调节作用

英文题名：Potential Modulation of Lacticaseibacillus paracasei LPB27 on the Gut Flora

作者：张绍时[1,2];赵建[1,2];郭豫[1,2];崔倩倩[1,2];闫文杰[1,2]

第一作者：张绍时

机构：[1]北京联合大学生物化学工程学院,生物活性物质与功能食品北京市重点实验室,北京100023;[2]北京联合大学应用文理学院保健食品功能检测中心,北京100191

第一机构：北京联合大学应用文理学院|北京联合大学生物化学工程学院

年份：2026

卷号：47

期号：10

起止页码：404-411

中文期刊名：食品工业科技

外文期刊名：Science and Technology of Food Industry

收录：;北大核心:【北大核心2023】；

基金：国家重点研发计划项目(2023YFF1103802)。

语种：中文

中文关键词：保健食品;副干酪乳酪杆菌LPB27;肠道菌群;短链脂肪酸

外文关键词：health food;Lacticaseibacillus paracasei LPB27;intestinal flora;short-chain fatty acids

摘要：目的:探究婴幼儿肠道来源的副干酪乳酪杆菌LPB27对肠道菌群的调节作用及其潜在机制,为其作为新型益生菌制剂的开发提供理论依据。方法:参照《保健食品功能检验与评价方法(2023版)》中“有助于调节肠道菌群检验方法”将48只雄性BALB/c小鼠分为对照组、低剂量组、中剂量组与高剂量干预组,通过灌胃给予LPB27益生菌粉(0、0.08、0.17、0.50 g/kg·BW)21 d,监测体重、粪便目的菌群变化。采用16S rDNA高通量测序技术,进一步分析肠道菌群的群落组成及差异物种,并通过PICRUSt2预测代谢功能。最后,测定粪便中短链脂肪酸(SCFAs)含量。结果:经口给予小鼠副干酪乳杆菌LPB27益生菌粉21 d后,小鼠状态良好且体重平稳增加,粪便中的乳杆菌和双歧杆菌数量明显增加,致病菌肠杆菌、肠球菌和产气荚膜梭菌没有明显变化。可判定该受试样品有助于调节肠道菌群动物实验结果阳性。16S rDNA和SCFAs分析表明,LPB27可能通过靶向调控Akkermansia、Ruminococcus等益生菌属,重塑肠道菌群结构并激活SCFAs代谢通路,从而发挥调节肠道健康的作用。结论:副干酪乳酪杆菌LPB27具有可调节肠道菌群功能。其干预机制为:LPB27可激活L-Methionine BiosynthesisⅢ途径,显著富集益生菌Akkermansia和Ruminococcus,进而增加SCFAs(尤其是丁酸)等有益代谢物含量,构建“菌群-代谢物”协同调节网络,为将其开发为新型益生菌制剂、应用于肠道微生态调节领域,提供了科学理论依据。
Objective:This study aimed to investigate the regulatory effects of Lacticaseibacillus paracasei LPB27,a strain isolated from infant intestines,on gut microbiota and elucidate its underlying mechanisms,thereby providing a scientific basis for its potential development as a novel probiotic agent.Methods:A total of 48 male BALB/c mice were randomly assigned to four groups:A control group and low-dose,medium-dose,and high-dose intervention groups,following the guidelines outlined in the"Test Methods for Regulating Intestinal Flora"from the''Functional Evaluation Procedures and Test Methods for Health Foods(2023 Edition)''.The animals were administered LPB27 probiotic powder via gavage at doses of 0,0.08,0.17,and 0.50 g/kg body weight,respectively,over a period of 21 days.Body weight changes and alterations in target intestinal bacterial populations in fecal samples were monitored throughout the experiment.The composition and differential microbial species within the gut microbiota were analyzed using 16S rDNA high-throughput sequencing,while PICRUSt2 was employed for predictive functional profiling.Additionally,the concentrations of fecal short-chain fatty acids(SCFAs)were quantified.Results:Following the 21-day intervention,all mice remained in good health with consistent weight gain observed across groups.Notably,significant increases in the levels of Lactobacillus and Bifidobacterium were detected in the medium-and high-dose groups,particularly in the high-dose group.No significant changes were observed in the abundance of pathogenic bacteria,including Enterobacter,Enterococcus,and Clostridium perfringens.These findings confirm the efficacy of LPB27 in modulating intestinal flora in the animal model.Further analysis using 16S rDNA sequencing and SCFA profiling revealed that LPB27 may exert its beneficial effects by modulating key genera such as Akkermansia and Ruminococcus,reshaping the microbial community structure,and enhancing SCFA metabolic pathways.Specifically,butyrate production was significantly elevated in the high-dose group.Conclusion:Lacticaseibacillus paracasei LPB27 demonstrates effective regulation of gut microbiota through a synergistic"microbiota-metabolite"network,involving activation of the L-Methionine Biosynthesis III pathway,enrichment of beneficial genera such as Akkermansia and Ruminococcus,and increased production of beneficial metabolites,particularly butyrate.This study provides a solid scientific foundation for the development of LPB27 as a novel probiotic formulation aimed at regulating intestinal microecology.